New Sales and Marketing Director at XVIVO Perfusion
Christer de Flon has been appointed as Sales and Marketing Director, with responsibility for all marketing and sales activities within Xvivo Perfusion. He joins the company from Blå Stjärnan, where he is CEO.
Christer de Flon has previous work experience from senior management positions at Hässle, Astra-Hässle and AstraZeneca. He has also been the CEO of Carlsson Research AB, the Deputy CEO of Vitrolife AB and most recently the CEO of Blå Stjärnan’s Veterinary Hospital. Christer takes up his appointment no later than May 1, 2013.
“With his great experience of sales and marketing, Christer will be an excellent asset for us in the work of establishing STEEN Solution™ on the market. We warmly welcome Christer to XVIVO Perfusion and the assignment as Sales and Marketing Director. I am pleased that our company is gaining an extremely competent and experienced co-worker,” says Magnus Nilsson, XVIVO Perfusion’s CEO.
November 21, 2012
XVIVO Perfusion AB (publ)
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se .
Xvivo Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com
For further information please contact:
Magnus Nilsson, CEO, tel: 46 31 788 21 50, e-mail: firstname.lastname@example.org
Christoffer Rosenblad, CFO, tel: 46 73 519 21 59, e-mail: email@example.com
For further information on Xvivo Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 21, 2012 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.